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To the Editor:
Interstitial lung diseases (ILDs) that present in childhood (chILD) are seen far less frequently than ILDs
presenting in adults which themselves constitute rare disorders [1]. Histopathological [2, 3] and imaging [4]
characterisation of chILD disease subtypes therefore lags behind adult ILDs. The field has also been
constrained by comparisons with disease morphology in adults, despite the developmental differences in
terms of growth and healing in the paediatric lung, which may alter disease patterns and distributions. The
American Thoracic Society [5] and European [1] chILD management guidelines both specify a pivotal role
for computed tomography (CT) imaging in the work-up of chILD patients to: 1) determine whether a
chILD is present or not; and 2) where possible, to make a specific diagnosis of the underlying cause. For
the second aim to be achieved, diagnostic reviews need to be reproducible between experts. Our study
uniquely examined agreement between observers of varying experience in the CT evaluation of chILD to
inform whether the current status of CT imaging and knowledge can be diagnostic of specific chILDs. We
hypothesised that observer agreement for chILD groups and diagnoses would be limited. The study was not
designed to relate CT agreement to final diagnosis. As a secondary analysis, we examined how CT
interpretation differed between observers in children under and over 2 years of age.
84 patients (<2 years, n=35) from 13 countries, referred to the Royal Brompton Hospital paediatric ILD
unit from 1999 to 2014 were re-evaluated by 10 observers: three chILD sub-specialist radiologists with
>25 years’ experience (C.M. Owens, P. Garcia-Peña, A.S. Brody) Q1
¶
; four chILD pulmonologists with
>20 years’ experience (S. Cunningham, T.J. Vece, P. Aurora, A. Moreno-Galdó); and three radiologists with
5–10 years’ chILD experience (A. Calder, P. Toma, T.A. Watson). Consecutive patients were chosen and
included in the study if clinically indicated DICOM format CTs were retrievable and of acceptable quality
(high-resolution, ⩽2 mm slice thickness) as determined by an independent radiologist ( J. Jacob).
Observers were given details of patient sex and age. Each scorer provided up to three choices when
assigning a chILD diagnostic group or individual chILD diagnosis from a preselected list. For each choice,
a measure of group/diagnostic likelihood was also assigned with confidence scores ranging from 0% to
100%: 100%=pathognomonic, 70–90%=high confidence, 40–60%=moderate confidence, 10–30%=low
confidence, 0%=no confidence. The choices were based on previous histopathological work [2].
The Fleiss Kappa evaluated observer agreement for first-choice chILD groups/individual diagnoses. For
chILD groups/individual diagnoses where agreement was at least fair, observer confidence was examined
using linear weighted kappas [6]. Results were reanalysed according to patient age (<2 years versus
>2 years, the conventional dichotomy in chILD classifications [7]) given the variable prevalence of chILD
disease groups/individual diagnoses across these age ranges. Agreement was also examined in observer
subgroups (senior versus junior radiologists versus senior pulmonologists). Statistical analyses were
performed with R: A language and environment for statistical computing [8]. Approval for the study was
obtained from the Institutional Research Committee of the Royal Brompton Hospital (Project 1157).
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840 first-choice chILD group/diagnostic assignations were made by the 10 observers (table 1). chILD
groups/diagnoses whose frequency was <10% of the total number of first-choice diagnoses in patients
under and over 2 years of age, were grouped as “others”, in accord with previous studies [9]. Four chILD
groups were analysed: airways disease (n=247), interstitial pneumonia (n=326), developmental/undefined
aetiology disorders (n=147) and others (n=120). Five chILD diagnoses could be analysed in patients
<2 years: infection (n=48), chronic pneumonitis of infancy (CPI; n=47), pulmonary alveolar proteinosis
(PAP, n=53), developmental/undefined aetiology disorders (n=83) and others (n=119). Four chILD
diagnoses could be analysed in patients >2 years: obliterative bronchiolitis (n=48), infection (n=86),
fibrotic nonspecific interstitial pneumonia (fNSIP; n=47) and others (n=309).
TABLE 1 Assignations of first-choice individual childhood interstitial lung disease (chILD)
group or diagnosis in children under 2 years of age (n=35) and over 2 years of age (n=49) by 10
observers
chILD category chILD group/diagnosis Numbers of
first-choice
assignations
<2 years >2 years
chILD groups Normal 3 18
Airways disease# 77 170
Interstitial pneumonia 126 200
Developmental/undefined aetiology disorders¶ 99 48
Unclassifiable 4 13
Bronchopulmonary dysplasia 29 10
Other 12 31
chILD Diagnoses Exudative bronchiolitis 4 2
Constrictive obliterative bronchiolitis 10 48
Infection 48 86
Chronic pneumonitis of infancy 47 12
Pulmonary alveolar proteinosis 53 24
Desquamative interstitial pneumonia 8 13
Nonspecific interstitial pneumonia (cellular) 16 34
Diffuse alveolar damage 3 8
Fibrotic nonspecific interstitial pneumonia 1 47
Organising pneumonia 0 30
Diffuse alveolar haemorrhage 1 11
Alveolar microlithiasis 0 3
Sarcoidosis 0 6
Langerhans cell histiocytosis 1 12
Lung growth abnormality/chronic disease of prematurity 83 12
Pulmonary interstitial glycogenosis 11 0
Neuroendocrine cell hyperplasia of infancy 30 15
Lymphoid interstitial pneumonia 1 23
Diffuse lymphoid hyperplasia 1 2
Lymphomatoid granulomatosis 1 4
Follicular bronchiolitis 0 6
Bronchus-associated lymphoid tissue 0 1
Primary pulmonary arterial hypertension 1 4
PVOD/PCH 3 5
Thromboembolic disease 1 3
Lymphangiomatosis 1 1
Lymphangiectasia (primary and secondary) 7 7
Secondary vasculopathies (e.g. due to cardiac disease) 6 2
Primary and secondary pulmonary vasculitis 1 14
Neoplasms 0 9
Alternate diagnosis 11 24
PVOD: pulmonary veno-occlusive disease; PCH: pulmonary capillary haemangiomatosis. #: airways
disease included infection and obliterative and exudative bronchiolitis; ¶: developmental/undefined
aetiology disorders included growth disorders such as alveolar hypoplasia, neuroendocrine cell
hyperplasia of infancy and pulmonary interstitial glycogenosis.
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When subanalysed according to patient age, observer agreement for first-choice chILD groups was
moderate for airways disease and interstitial pneumonia in patients >2 years, but only fair in patients
<2 years (table 2). There was generally less observer variation between senior radiologists than
pulmonologists. In patients <2 years senior radiologists demonstrated better agreement than other
observers. High confidence chILD group assignations (>70%) were more common in children >2 years and
increased with observer seniority (data not shown). Encouragingly, agreement for diagnostic groups was
best for infection/airways disease where conservative management without biopsy may be preferable.
Observer agreement in assigning first-choice individual chILD diagnoses was moderate for obliterative
bronchiolitis (in children >2 years), and fair for other diagnoses except CPI where agreement was poor.
Further analyses were only performed in individual diagnoses where agreement was at least fair. Observer
agreement for diagnostic likelihoods were moderate for obliterative bronchiolitis (children >2 years of age),
but were at best only fair for other diagnoses, regardless of patient age (data not shown). Observer
agreement for diagnostic likelihood of infection in children <2 years was poor across all observer subgroups.
We report poor agreement between even experienced thoracic radiologists for the identification of most
chILD groups and individual diagnoses across ages. The lower observer agreement for individual chILD
diagnoses compared with chILD diagnostic groups may reflect differing methods by which radiologists
classify CT appearances. Some observers might classify according to histological pattern and distinguish
features of NSIP from PAP in a child >2 years, while others might classify according to suspected aetiology
and recognise both patterns as suggesting a surfactant protein disorder. Our findings stress the need for a
new common uniform descriptor language for CT appearances, because the present system is not
reproducible and therefore confusing.
The current classification system in chILD is based on histopathological diagnoses [2, 7], and as occurred
with adult fibrosing lung diseases, it is hoped that histopathological descriptors will inform those CT
features that are of importance in delineating childhood disease. Two early studies examining diagnostic
accuracy using radiological–histopathological correlations in a small subset of chILD patients demonstrated
that CT features could identify histopathological diagnoses with acceptable accuracy [4, 10]. However,
prior to the evaluation of CT diagnostic accuracy it is essential to understand whether expert readers can
coalesce on a single diagnosis with sufficient frequency that a single CT diagnosis can be compared to a
single histopathological diagnosis.
Study limitations included the time frame over which cases were acquired, where CT imaging protocols
and quality varied widely. However, imaging heterogeneity is an unavoidable constraint when examining
real-world paediatric data and we actively sought to draw real-world conclusions on chILD observer
agreement. Limiting clinical information to patient age and sex might have increased observer
disagreement. However rather than examining diagnostic accuracy, our a priori study aim was to
understand the limitations of CT interrogation of chILD and identify those conditions where pattern
recognition alone is insufficient to make a confident diagnosis. Though the study case mix from a tertiary
centre is likely to have been weighted towards more challenging presentations of disease, chILD cases are
only seen with sufficient frequency to allow analysis in such centres.
TABLE 2 Fleiss kappa values for observer agreement for first choice group assignation in the 84 study cases. Sub-analyses
are shown for patients under 2 years of age (n=35) and over 2 years of age (n=49)
Patient groups Observer groups All cases Airways disease# Interstitial pneumonia Developmental/undefined¶
All patients All observers 0.30 (0.28–0.32) 0.37 (0.34–0.41) 0.36 (0.33–0.40) 0.18 (0.15–0.21)
Senior radiologists 0.35 (0.27–0.42) 0.46 (0.34–0.58) 0.44 (0.31–0.56) 0.16 (0.04–0.29)
Senior pulmonologists 0.28 (0.23–0.33) 0.34 (0.25–0.42) 0.36 (0.27–0.45) 0.21 (0.12–0.29)
Junior radiologists 0.31 (0.23–0.38) 0.45 (0.33–0.57) 0.39 (0.27–0.51) 0.07 (−0.06–0.19)
Patients <2 years of
age
All observers 0.22 (0.19–0.25) 0.28 (0.23–0.33) 0.30 (0.25–0.35) 0.14 (0.09–0.19)
Senior radiologists 0.36 (0.24–0.48) 0.61 (0.42–0.80) 0.46 (0.26–0.65) 0.15 (−0.05–0.34)
Senior pulmonologists 0.18 (0.10–0.26) 0.24 (0.11–0.38) 0.26 (0.12–0.39) 0.16 (0.02–0.29)
Junior radiologists 0.13 (0.01–0.24) 0.35 (0.16–0.54) 0.19 (−0.00–0.38) −0.05 (−0.24–0.14)
Patients >2 years of
age
All observers 0.33 (0.31–0.36) 0.40 (0.36–0.45) 0.40 (0.36–0.44) 0.11 (0.07–0.15)
Senior radiologists 0.31 (0.21–0.41) 0.36 (0.20–0.53) 0.42 (0.26–0.58) 0.12 (−0.04–0.29)
Senior pulmonologists 0.32 (0.25–0.40) 0.36 (0.24–0.47) 0.43 (0.32–0.55) 0.09 (−0.02–0.21)
Junior radiologists 0.42 (0.32–0.53) 0.52 (0.36–0.68) 0.48 (0.32–0.64) 0.09 (−0.07–0.25)
#: airways disease included infection and obliterative and exudative bronchiolitis; ¶: developmental/undefined aetiology disorders included
growth disorders such as alveolar hypoplasia, neuroendocrine cell hyperplasia of infancy and pulmonary interstitial glycogenosis.
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Our study is the largest examination of CT imaging in chILD cases, scored by the largest number of
observers, to date, who importantly were from different specialties. We demonstrate that making chILD
diagnoses on CT is difficult, even amongst sub-specialists. Considering the current state of knowledge in
the field, we found that agreement for chILD diagnostic groups was generally better than for individual
diagnoses and was highest amongst senior radiologists. Further detailed work is needed to understand if,
with studies and training, improvements in CT diagnostic agreement are possible. Additionally, the ability
of the multidisciplinary team to improve diagnostic confidence by augmenting radiology with clinical,
functional and haematological results, as per guideline recommendations [1, 5] requires further study.
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